ArticleJHLT open2025
Beyond boundaries: Redefining the donor frontier in pediatric lung transplantation.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current opinion in pediatrics: pediatric lung transplantation in the 21 st century.Current opinion in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung transplantation remains the optimal treatment for children with end-stage lung disease, yet donor organ shortage represents the greatest obstacle to transplantation. In 2023, only 31 pediatric lung transplants were performed in the United States, with 9% of recovered lungs ultimately not transplanted. Pediatric waitlist mortality has increased, particularly for patients under one year of age, necessitating innovative strategies to expand the donor pool. Methods: This review examines emerging strategies to combat organ shortage in pediatric lung transplantation, including extended criteria donors, deceased cardiac death (DCD) organ donation, ex-vivo lung perfusion (EVLP), graft size reduction techniques, living donor lobar transplantation, and utilization of hepatitis C and HIV-positive donor organs. We analyzed current literature and clinical outcomes data to assess the feasibility and safety of these approaches in pediatric populations. Results: Extended criteria donors now account for 80% of lung transplants without compromising short- and mid-term pediatric outcomes. DCD lung transplantation demonstrates comparable survival rates to brain-dead donors, with only 14 DCD organs used in pediatric programs between 2004-2022. EVLP shows promise in preserving organ viability and reducing primary graft dysfunction. Hepatitis C-positive donors demonstrate excellent outcomes with direct-acting antiviral therapy in adult patients, but scant literature is available in the pediatric population. Reduced-size grafts and living donor procedures offer solutions for size-mismatched recipients. Conclusions: Multiple innovative strategies show potential for expanding the pediatric lung donor pool. While adult data demonstrates safety and efficacy, pediatric-specific research remains limited. Continued scientific inquiry, active donor management protocols, and interdisciplinary cooperation are essential to safely implement these approaches and improve access to life-saving transplantation for children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.